Evidence map›Paper›PMID 29874250›Full record

ArticlePloS one2018

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.

Julia M Grottenthaler, Christoph R Werner, Martina Steurer, Ulrich Spengler, Thomas Berg, Cornelius Engelmann, Heiner Wedemeyer, Thomas von Hahn, Wolfgang Stremmel, Anita Pathil and 11 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 1 country.

Julia M GrottenthalerDepartment of Gastroenterology, Hepatology, and Infectiology, University Hospital Tuebingen, Tuebingen, Germany.ORCID 0000-0001-9122-0962
Christoph R WernerDepartment of Gastroenterology, Hepatology, and Infectiology, University Hospital Tuebingen, Tuebingen, Germany.
Martina SteurerDepartment of Gastroenterology, Hepatology, and Infectiology, University Hospital Tuebingen, Tuebingen, Germany.
Ulrich SpenglerGerman Center for Infection Research (DZIF) partner site, Tuebingen, Bonn, Hannover, Heidelberg, Munich, Germany.
Thomas BergDivision of Gastroenterology and Hepatology, University Hospital Leipzig, Leipzig, Germany.
Cornelius EngelmannDivision of Gastroenterology and Hepatology, University Hospital Leipzig, Leipzig, Germany.
Heiner WedemeyerGerman Center for Infection Research (DZIF) partner site, Tuebingen, Bonn, Hannover, Heidelberg, Munich, Germany.
Thomas von HahnGerman Center for Infection Research (DZIF) partner site, Tuebingen, Bonn, Hannover, Heidelberg, Munich, Germany.
Wolfgang StremmelGerman Center for Infection Research (DZIF) partner site, Tuebingen, Bonn, Hannover, Heidelberg, Munich, Germany.
Anita PathilGerman Center for Infection Research (DZIF) partner site, Tuebingen, Bonn, Hannover, Heidelberg, Munich, Germany.
Ulrich SeyboldGerman Center for Infection Research (DZIF) partner site, Tuebingen, Bonn, Hannover, Heidelberg, Munich, Germany.
Eckart SchottDepartment of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Usha BlessinDepartment of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Christoph SarrazinDepartment of Gastroenterology and Hepatology, University Hospital Frankfurt, Frankfurt, Germany.
Martin-Walter WelkerDepartment of Gastroenterology and Hepatology, University Hospital Frankfurt, Frankfurt, Germany.
Ellen HarrerDepartment of Internal Medicine 3, Institute of Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Stefan ScholtenPraxis Hohenstaufenring, Cologne, Germany.
Clemens HinterleitnerGerman Center for Infection Research (DZIF) partner site, Tuebingen, Bonn, Hannover, Heidelberg, Munich, Germany.ORCID 0000-0003-2416-9399
Ulrich M LauerGerman Center for Infection Research (DZIF) partner site, Tuebingen, Bonn, Hannover, Heidelberg, Munich, Germany.
Nisar P MalekDepartment of Gastroenterology, Hepatology, and Infectiology, University Hospital Tuebingen, Tuebingen, Germany.
Christoph P BergDepartment of Gastroenterology, Hepatology, and Infectiology, University Hospital Tuebingen, Tuebingen, Germany.
German Center for Infection Research · DECharité - Universitätsmedizin Berlin · DEGoethe University Frankfurt · DEHeidelberg University · DEMedizinische Hochschule Hannover · DEUniversity Hospital Leipzig · DEUniversitätsklinikum Erlangen · DEUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this multicenter retrospective study was to investigate safety and efficacy of direct acting antiviral (DAA) treatment in the rare subgroup of patients with HCV/HIV-coinfection and advanced liver cirrhosis on the liver transplant waiting list or after liver transplantation, respectively.

methodsWhen contacting 54 German liver centers (including all 23 German liver transplant centers), 12 HCV/HIV-coinfected patients on antiretroviral combination therapy were reported having received additional DAA therapy while being on the waiting list for liver transplantation (patient characteristics: Child-Pugh A (n = 6), B (n = 5), C (n = 1); MELD range 7-21; HCC (n = 2); HCV genotype 1a (n = 8), 1b (n = 2), 4 (n = 2)). Furthermore, 2 HCV/HIV-coinfected patients were denoted having received DAA therapy after liver transplantation (characteristics: HCV genotype 1a (n = 1), 4 (n = 1)).

resultsApplied DAA regimens were SOF/DAC (n = 7), SOF/LDV/RBV (n = 3), SOF/RBV (n = 3), PTV/r/OBV/DSV (n = 1), or PTV/r/OBV/DSV/RBV (n = 1), respectively. All patients achieved SVR 12, in the end. In one patient, HCV relapse occurred after 24 weeks of SOF/DAC therapy; subsequent treatment with 12 weeks PTV/r/OBV/DSV achieved SVR 12. One patient underwent liver transplantation while on DAA treatment. Analysis of liver function revealed either stable parameters or even significant improvement during DAA therapy and in follow-up. MELD scores were found to improve in 9/13 therapies in patients on the waiting list for liver transplantation; in only 2 patients a moderate increase of MELD scores persisted at the end of follow-up.

conclusionDAA treatment was safe and highly effective in this nation-wide cohort of patients with HCV/HIV-coinfection awaiting liver transplantation or being transplanted.

Indexed as

Liver TransplantationAdultAntiretroviral Therapy, Highly ActiveAntiviral AgentsCoinfectionDrug Therapy, CombinationFemaleGermanyHepacivirusHepatitis CHIV-1HIV InfectionsHumansLiver CirrhosisMaleMiddle AgedAntiviral AgentsRibavirinRitonavirSofosbuvir

Identifiers

PMID29874250
PMCPMC5991346
OpenAlexW2806144316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.